在肿瘤完全切除后,在 ctDNA 阳性或具有高危病理特征的 I 期腺癌 NSCLC 受试者中进行 Dato-DXd 辅助疗法联合 Rilvegostomig 或 Rilvegostomig 单药疗法与标准护理的 III 期随机研究 (TROPION-Lung12)
在 I 期腺癌非小细胞肺癌受试者中,在肿瘤完全切除后,辅助 Datopotamab Deruxtecan (Dato-DXd) 联合 Rilvegostomig 或 Rilvegostomig 单药疗法与标准护理的 III 期、随机、开放标签全球研究谁是 ctDNA 阳性或具有高风险病理特征 (TROPION-Lung12)
This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.
研究概览
地位
条件
详细说明
The primary objective of the study is to assess the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig relative to SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
Nova Scotia
-
Halifax、Nova Scotia、加拿大、B3H 2Y9
- Research Site
-
-
Ontario
-
Oshawa、Ontario、加拿大、L1G 2B9
- Research Site
-
-
Quebec
-
Montreal、Quebec、加拿大、H2X 3J4
- Research Site
-
-
-
-
-
Kaohsiung City、台湾、80756
- Research Site
-
Taipei、台湾、10002
- Research Site
-
Taipei、台湾、112
- Research Site
-
Taipei、台湾、114
- Research Site
-
Taoyuan、台湾、333
- Research Site
-
-
-
-
-
Ankara、土耳其(türkiye)、06280
- Research Site
-
Ankara、土耳其(türkiye)、06010
- Research Site
-
Mersin、土耳其(türkiye)、33240
- Research Site
-
-
-
-
-
Barretos、巴西、14784-057
- Research Site
-
Brasília、巴西、70200-730
- Research Site
-
Florianópolis、巴西、88034-000
- Research Site
-
São Paulo、巴西、01323-903
- Research Site
-
Teresina、巴西、64049-200
- Research Site
-
-
-
-
-
Bunkyō City、日本、113-8603
- Research Site
-
Chiba、日本、260-0877
- Research Site
-
Chūōku、日本、104-0045
- Research Site
-
Fukuoka、日本、812-8582
- Research Site
-
Hidaka-shi、日本、350-1298
- Research Site
-
Hiroshima、日本、734-8551
- Research Site
-
Hiroshima、日本、730-8518
- Research Site
-
Iwakuni-shi、日本、740-8510
- Research Site
-
Kashiwa、日本、277-8577
- Research Site
-
Kitaadachi-gun、日本、362-0806
- Research Site
-
Kobe、日本、650-0017
- Research Site
-
Kumamoto、日本、860-8556
- Research Site
-
Kōtoku、日本、135-8550
- Research Site
-
Nagoya、日本、464-8681
- Research Site
-
Niigata、日本、951-8566
- Research Site
-
Osakasayama-shi、日本、589-8511
- Research Site
-
Sapporo、日本、003-0804
- Research Site
-
Sendai、日本、980-8574
- Research Site
-
Sendai、日本、980-0873
- Research Site
-
Wakayama、日本、641-8510
- Research Site
-
Yokohama、日本、241-8515
- Research Site
-
-
-
-
-
Bangkok、泰国、10400
- Research Site
-
Bangkoknoi、泰国、10700
- Research Site
-
Banphaeo、泰国、74120
- Research Site
-
Dusit、泰国、10300
- Research Site
-
Hat Yai、泰国、90110
- Research Site
-
Muang、泰国、50200
- Research Site
-
Muang、泰国、40002
- Research Site
-
Ratchathewi、泰国、10400
- Research Site
-
-
-
-
Arizona
-
Tucson、Arizona、美国、85724
- Research Site
-
-
California
-
Duarte、California、美国、91010
- Research Site
-
Glendale、California、美国、91204
- Research Site
-
Los Angeles、California、美国、90089
- Research Site
-
-
Colorado
-
Lone Tree、Colorado、美国、80124
- Research Site
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20007
- Research Site
-
-
Florida
-
Jacksonville、Florida、美国、32224
- Research Site
-
St. Petersburg、Florida、美国、33709
- Research Site
-
-
Illinois
-
Chicago、Illinois、美国、60637
- Research Site
-
Evanston、Illinois、美国、60201
- Research Site
-
Zion、Illinois、美国、60099
- Research Site
-
-
Kansas
-
Kansas City、Kansas、美国、66160
- Research Site
-
-
Kentucky
-
Lexington、Kentucky、美国、40503
- Research Site
-
-
Maryland
-
Baltimore、Maryland、美国、21237
- Research Site
-
-
Michigan
-
Farmington Hills、Michigan、美国、48334
- Research Site
-
Grand Rapids、Michigan、美国、49503
- Research Site
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55407
- Research Site
-
-
Montana
-
Billings、Montana、美国、59102
- Research Site
-
-
Nebraska
-
Omaha、Nebraska、美国、68130
- Research Site
-
-
New York
-
East Syracuse、New York、美国、13057
- Research Site
-
Mineola、New York、美国、11501
- Research Site
-
New York、New York、美国、10016
- Research Site
-
New York、New York、美国、10065
- Research Site
-
-
Oregon
-
Portland、Oregon、美国、97239
- Research Site
-
-
Pennsylvania
-
Bethlehem、Pennsylvania、美国、18015
- Research Site
-
Philadelphia、Pennsylvania、美国、19107
- Research Site
-
Pittsburgh、Pennsylvania、美国、15212
- Research Site
-
-
Tennessee
-
Knoxville、Tennessee、美国、37920
- Research Site
-
Memphis、Tennessee、美国、38120
- Research Site
-
Nashville、Tennessee、美国、37203
- Research Site
-
-
Texas
-
Austin、Texas、美国、78745
- Research Site
-
Dallas、Texas、美国、75231
- Research Site
-
Houston、Texas、美国、77030
- Research Site
-
San Antonio、Texas、美国、78217
- Research Site
-
-
Virginia
-
Fairfax、Virginia、美国、22031
- Research Site
-
-
Washington
-
Seattle、Washington、美国、98104
- Research Site
-
-
Wisconsin
-
Madison、Wisconsin、美国、53792
- Research Site
-
-
-
-
-
Hanoi、越南、100000
- Research Site
-
Ho Chi Minh City、越南、700000
- Research Site
-
Hà Nội、越南、100000
- Research Site
-
Vinh、越南、460000
- Research Site
-
-
-
-
-
Hong Kong、香港、999077
- Research Site
-
-
-
-
-
Kuala Lumpur、马来西亚、59100
- Research Site
-
Kuala Lumpur、马来西亚、50586
- Research Site
-
Kuching、马来西亚、93586
- Research Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Histologically documented treatment-naive Stage I (T < 4 cm, AJCC 8th ed) adenocarcinoma NSCLC
- Complete surgical resection (R0) of the primary NSCLC
- Unequivocal no evidence of disease at post-surgical
- Pre-surgical ctDNA-positive result (Stage IA or IB) OR presence of at least one high-risk pathological feature (visceral pleural invasion (VPI), lymphovascular invasion (LVI), high-grade histology) (Stage IB only)
- ECOG of 0 or 1, life expectancy of > 6 months and complete recovery after surgery
- Adequate bone marrow reserve and organ function
Exclusion Criteria:
- Sensitizing EGFR mutation and/or ALK alteration
- History of non-infectious ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
- Significant pulmonary function compromise
- History of another primary malignancy within 3 years (with exceptions)
- Any evidence of severe or uncontrolled systemic diseases, including but not limited to bleeding diseases, active infection and cardiac disease
- Active or prior documented autoimmune or inflammatory disorders (with exceptions)
- Active infection with tuberculosis, hepatitis B or C virus, hepatitis A, or known HIV infection that is not well controlled
- History of active primary immunodeficiency
- Clinically significant corneal disease
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Dato-DXd + rilvegostomig
Participants in the Dato-DXd in combination with rilvegostomig group will receive Dato-DXd and rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W). |
Datopotamab Deruxtecan IV (intravenous)
其他名称:
Rilvegostomig IV (intravenous)
其他名称:
|
|
实验性的:Rilvegostomig
Participants in the rilvegostomig monotherapy group will receive rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W). |
Rilvegostomig IV (intravenous)
其他名称:
|
|
有源比较器:Standard of Care (SoC)
Patients in SoC group will undergo observation or will receive Investigator's Choice of Chemotherapy (ICC). |
Carboplatin IV (intravenous), Active Comparator Cisplatin IV (intravenous), Active Comparator Etoposide IV (intravenous), Active Comparator Pemetrexed IV (intravenous), Active Comparator Vinorelbine IV (intravenous), Active Comparator UFT Oral route of administration, Active Comparator |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Disease-Free Survival (DFS) using BICR in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
大体时间:From date of randomisation up to approximately 10 years.
|
The analysis will include all randomised participants as randomised. All events will be included, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy. The measure of interest is the HR of DFS. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components. |
From date of randomisation up to approximately 10 years.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall Survival (OS) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
大体时间:From date of randomisation up to approximately 10 years.
|
The analysis will include all randomised participants as randomised. All deaths will be included, regardless of whether the participant withdraws from therapy or receives another anti-cancer therapy. The measure of interest is the HR of OS. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components. |
From date of randomisation up to approximately 10 years.
|
|
Participant-reported physical function in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
大体时间:Measured at weeks 12, 24 and 48.
|
The analysis will include all randomised participants as randomised. The physical function will be measured by the PROMIS SF PF 8c. Data from PROMIS SF PF 8c will capture participants' perceived ability to perform specific activities from daily life and will be scored on a 5-point rating scale. The measure of interest will be the between treatment group difference in adjusted mean in physical function scores. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components. |
Measured at weeks 12, 24 and 48.
|
|
Participant-reported GHS/QoL in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
大体时间:Measured at weeks 12, 24 and 48.
|
The analysis will include all randomised participants as randomised. The GHS/QoL scores will be measured by the GHS/QoL scale from EORTC IL172. The measure of interest will be the between treatment group difference in adjusted mean in GHS/QoL scores. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components. |
Measured at weeks 12, 24 and 48.
|
|
Pharmacokinetics (PK)
大体时间:Up to 30 or 90 days post-last dose of study intervention.
|
Concentration of Dato-DXd, total anti-TROP2 antibody, and MAAA-1181a (payload deruxtecan) in plasma or serum. |
Up to 30 or 90 days post-last dose of study intervention.
|
|
Pharmacokinetics (PK)
大体时间:Up to 30 or 90 days post-last dose of study intervention.
|
Concentration of rilvegostomig in plasma or serum. |
Up to 30 or 90 days post-last dose of study intervention.
|
|
Pharmacokinetics (PK)
大体时间:Up to 30 or 90 days post-last dose of study intervention.
|
PK parameters (peak and through concentrations). |
Up to 30 or 90 days post-last dose of study intervention.
|
|
Immunogenicity
大体时间:Up to 30 or 90 days post-last dose of study intervention.
|
Presence of ADAs for Dato-DXd and rilvegostomig (confirmatory results: titres and neutralising antibodies for confirmed positive samples). |
Up to 30 or 90 days post-last dose of study intervention.
|
合作者和调查者
赞助
合作者
调查人员
- 首席研究员:David Jones, MD、Memorial Sloan Kettering Cancer Center, New York, United States of America
- 首席研究员:Enriqueta Felip, MD、Vall d'Hebron Hospital, Barcelona, Spain
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
- 按部位分类的肿瘤
- 肿瘤
- 呼吸道疾病
- 组织学类型的肿瘤
- 肺部疾病
- 肿瘤、腺体和上皮
- 呼吸道肿瘤
- 胸部肿瘤
- 肺肿瘤
- 癌
- 癌,支气管癌
- 支气管肿瘤
- 癌,非小细胞肺癌
- 腺癌
- 氨基酸,肽和蛋白质
- 有机化学品
- 杂环化合物
- 杂环化合物,2环
- 杂环化合物,融合环
- 碳氢化合物
- 碳氢化合物,循环
- 碳水化合物
- 生物碱
- Podophyllotoxin
- 四氢乙烯甲烯烃
- 萘
- 多环芳烃
- 碳氢化合物,芳香族
- 多环化合物
- 葡萄糖剂
- 糖苷
- 吲哚
- 无机化学物质
- 氯化合物
- 氮化合物
- 协调配合物
- 鸟嘌呤
- 低黄嘌呤
- 丘脑
- 嘌呤
- 谷氨酸
- 氨基酸,酸性
- 氨基酸
- 氨基酸,二羧酸
- VINCA生物碱
- Secologanin色素生物碱
- 吲哚生物碱
- 吲哚衍生物
- 吲哚王
- 白金化合物
- 长春瑞滨
- 培美曲塞
- 依托泊苷
- 卡铂
- 顺铂
其他研究编号
- D926TC00001
- 2024-512195-35-00 (注册表标识符:CTIS)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD 共享时间框架
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.
For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD 共享访问标准
When a request has been approved, AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool.
Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD 共享支持信息类型
- 研究方案
- 树液
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.